Real-life experiences with goal-directed prohemostatic therapy with fibrinogen concentrate, prothrombin complex concentrate, and recombinant factor VIIa: a retrospective study of 287 consecutive patients.

The Danish Capital Region Blood Bank operates a 24/7 on-call service staffed with physicians specialized in hemostatic management to guide clinicians in hemostatic resuscitation, including administration of prohemostatic therapy (PHT). The outcome of patients who receive PHT as part of hemostatic re...

Descripción completa

Detalles Bibliográficos
Publicado en:Scandinavian Journal of Clinical & Laboratory Investigation. Supplement Vol. 82; no. 2; pp. 156 - 162
Autores principales: Vigstedt, Martin, Henriksen, Hanne H., Chaachouh, Hadi W., Stensballe, Jakob, Johansson, Pär I.
Formato: research tables/charts Journal Article
Publicado: Taylor & Francis Ltd Apr2022
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=159093400&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 159093400
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        0085591X
        8ZPW
      jtl: Scandinavian Journal of Clinical & Laboratory Investigation. Supplement
      issn: 0085591X
      maglogo: Y
    pubinfo:
      dt: Apr2022
      vid: 82
      iid: 2
      pid: 377
      pub: Taylor & Francis Ltd
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        159093400
        159093400
        159093400
        10.1080/00365513.2022.2040048
        159093400
      ppf: 156
      ppct: 6
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Real-life experiences with goal-directed prohemostatic therapy with fibrinogen concentrate, prothrombin complex concentrate, and recombinant factor VIIa: a retrospective study of 287 consecutive patients.
      aug:
        au:
          Vigstedt, Martin
          Henriksen, Hanne H.
          Chaachouh, Hadi W.
          Stensballe, Jakob
          Johansson, Pär I.
        affil: Section for Transfusion Medicine, Capital Region Blood Bank, Copenhagen University Hospital, Copenhagen, Denmark
      sug:
        subj:
          Hemorrhage Therapy
          Hemorrhage Prognosis
          Hemostatic Techniques Methods
          Fibrinogen Therapeutic Use
          Prothrombin Therapeutic Use
          Blood Coagulation Factors Therapeutic Use
          Treatment Outcomes Evaluation
          Human
          Retrospective Design
          Record Review
          Denmark
          Thrombelastography
          Descriptive Statistics
          Survival Analysis
          Hemorrhage Mortality
      ab: The Danish Capital Region Blood Bank operates a 24/7 on-call service staffed with physicians specialized in hemostatic management to guide clinicians in hemostatic resuscitation, including administration of prohemostatic therapy (PHT). The outcome of patients who receive PHT as part of hemostatic resuscitation remains unanswered. The objective of this study was therefore to investigate clinical outcome of patients receiving PHT managed by the on-call service. We identified 287 patients who received PHT during 2015-16, of which 161 (59%) received fibrinogen concentrate (FC), 111 (39%) received prothrombin complex concentrate (PCC), and 15 (5%) received recombinant factor VIIa (rFVIIa) as the first product. Patients were critically ill with a 30-day mortality of 31%. Among FC recipients, cardiothoracic admission, non-trauma, and antithrombotics predicted survival. FC recipients had lower platelet count and thrombelastography clot strengths than the other PHT groups and within the group, these factors predicted mortality. The symptomatic thromboembolic event (TE) rate at 30 days was 5%. For PCC recipients, vitamin K antagonists predicted survival, while rivaroxaban predicted mortality. TE rate was 2%. We did not identify factors associated with survival in the small group of rFVIIa recipients. TE rate was 13%. In summary, trauma and coagulopathy predicted mortality in patients who received FC and our data suggest that optimization of PHT algorithms may be possible. Outcome of patients who received PCC was comparable to results reported elsewhere and its use may be safe in a setting as reported here. Recombinant FVIIa was rarely used but had the highest incidence of arterial thromboembolism.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N